Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05529654 · ClinicalTrials.gov registry record · NA
IMpella-Protected cArdiaC Surgery Trial (IMPACT)
A NA study of Left Ventricular Dysfunction, sponsored by Abiomed.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT05529654: Active NA study of Left Ventricular Dysfunction, sponsored by Abiomed.
NCT05529654 is a NA study of Left Ventricular Dysfunction that is active but no longer recruiting, run by Abiomed. The registered enrollment target is 100 participants, below the 1,224-participant average among 7 other Left Ventricular Dysfunction trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05529654, a NA study of Left Ventricular Dysfunction, is active but no longer recruiting, sponsored by Abiomed.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Trial is to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients, with the overall aim to evaluate if using Impella 5.5 with SmartAssist (Impella 5.5) peri-operatively improves early hemodynamics, end-organ function and clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.
Conditions Studied
Interventions
- DEVICE Impella 5.5 with SmartAssist
Study Locations (20)
New York
- NYU Langone Health - New York
- New York- Presbyterian Hospital/ Columbia University Medical Center - New York
- Montefiore Medical Center - The Bronx
California
- Keck School of Medicine - Los Angeles
- Tri-City Medical Center - San Diego
Massachusetts
- Mass General Hospital - Boston
- Brigham & Women's - Boston
Texas
- University of Texas Austin Dell Medical School/Ascension Texas - Austin
- Baylor Scott and White - Plano - Plano
Arkansas
- Cardiology Associates Research Group - Jonesboro
Florida
- NCH Rooney Heart Institute - Naples
Georgia
- Emory University Hospital - Atlanta
Minnesota
- Minneapolis Heart Institute Foundation/Abbott Northwestern Hospital - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2025-10 |
| Phase | NA |
What the registry record for NCT05529654 still lists
NCT05529654 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,224-participant average among 7 other Left Ventricular Dysfunction trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Left Ventricular Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Impella 5.5 with SmartAssist is the first listed.
NCT05529654 names 20 study sites across 15 states, led by New York, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05529654 about?
NCT05529654 is a clinical study titled "IMpella-Protected cArdiaC Surgery Trial (IMPACT)". The purpose of this Trial is to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients, with the overall aim to evaluate if using Impella 5.5 with SmartAssist (Impella 5.5) peri-operatively improves early hemodynamics, end-organ function and clinical...
What is the current status of trial NCT05529654?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2023-09-21. Estimated completion is 2025-10.
What conditions does trial NCT05529654 study?
This clinical trial studies the following conditions: Left Ventricular Dysfunction.
What interventions are being tested in trial NCT05529654?
The interventions under investigation include: Impella 5.5 with SmartAssist (DEVICE).
Who is sponsoring clinical trial NCT05529654?
This trial is sponsored by Abiomed, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05529654 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Left Ventricular Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The JenaValve ALIGN-AR LVAD Registry
RECRUITING · NA
-
Sodium Lowering Vascular Effects Trial
RECRUITING · NA
-
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
ACTIVE NOT RECRUITING · NA
-
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
RECRUITING
-
PRE-DETERMINE Cohort Study
ACTIVE NOT RECRUITING
-
Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI